The inducement grant consisted of time-based restricted stock units (“RSUs”) for 21,863 shares of Intellia’s common stock, with one-third of such RSUs vesting on February 1, 2026, 2027 and 2028.

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company ...

CEO John Leonard said the company will focus its resources largely on two late-stage programs amid a “challenging market environment.” Intellia Therapeutics Inc. is shedding employees and ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep the engine running until a potential commercial launch in 2027.

Intellia Therapeutics will cut about 27% of its workforce, or roughly 142 jobs, this year in a cost-savings push intended to support its operations into the first half of 2027, when it expects to ...

Intellia Therapeutics (NTLA) announced a strategic reorganization focused on key value drivers. The pipeline prioritization is intended to focus resources on high value programs – NTLA-2002 and ...

Intellia Therapeutics (NASDAQ:NTLA) said it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and discontinue development of NTLA-3001, which will result in the ...

Intellia Therapeutics shifts focus to NTLA-2002 for hereditary angioedema and nex-z for ATTR amyloidosis, advancing Phase 3 trials in 2025. Strategic reorganization includes a 27% workforce ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) on January 10 and set a price target of $39.00. Discover outperforming stocks and ...

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027 ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics NTLA in the last three months. The table below offers a condensed ...